S1800A
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
- NCT03971474 ↗
- Completed
- SWOG Cancer Research Network
- Standard
We haven't built an HCP commentary report on S1800A (gemcitabine hydrochloride, pembrolizumab and 5 more in Recurrent Lung Non-Small Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S1800A so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| Podcasts | 6 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Docetaxel; Gemcitabine; Gemcitabine Hydrochloride; Pembrolizumab; Pemetrexed; Pemetrexed Disodium; Ramucirumab
- Arms
- Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed) · Active comparator
- Arm B (ramucirumab, pembrolizumab) · Experimental
- Enrollment
- 166
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- May 28, 2019
- Primary completion
- Apr 14, 2022
- Results posted
- Yes
- Registry record
- NCT03971474 · updated Sep 3, 2024